{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-014620","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.848989+00:00","generated_at":"2026-05-22T15:57:10.533192+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"BioCardia initiates patient enrollment at University of Wisconsin for CardiAMP HF II Phase 3 trial","bullets":["University of Wisconsin now enrolling ischemic HFrEF patients in BioCardia's pivotal Phase 3 CardiAMP HF II trial.","Dr. Amish Raval named site PI and co-national PI for the study.","Trial uses autologous cell therapy with a three-tier composite outcome: death, nonfatal MACE, and quality-of-life.","Prior CardiAMP HF study met composite endpoint in elevated NTproBNP patients (p=0.02).","Advances include cell population analysis for dosing and FDA-approved Morph DNA steerable platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-014620","json":"https://secwatch.observer/filing/0001437749-25-014620.json","markdown":"https://secwatch.observer/filing/0001437749-25-014620.md","text":"https://secwatch.observer/filing/0001437749-25-014620.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774925014620/0001437749-25-014620-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774925014620/bcda20250505_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T15:57:10.533192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}